NO20041214L - Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer - Google Patents

Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer

Info

Publication number
NO20041214L
NO20041214L NO20041214A NO20041214A NO20041214L NO 20041214 L NO20041214 L NO 20041214L NO 20041214 A NO20041214 A NO 20041214A NO 20041214 A NO20041214 A NO 20041214A NO 20041214 L NO20041214 L NO 20041214L
Authority
NO
Norway
Prior art keywords
cancer
treatment
benzimidazole compounds
substituted benzimidazole
substituted
Prior art date
Application number
NO20041214A
Other languages
English (en)
Other versions
NO327008B1 (no
Inventor
Francois Clerc
Francois Hamy
Isabelle Depaty
Odile Angouillant-Boniface
Chantal Carrez
Manfred Roesner
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20041214L publication Critical patent/NO20041214L/no
Publication of NO327008B1 publication Critical patent/NO327008B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20041214A 2001-09-26 2004-03-23 Substituerte benzimidazolforbindelser og deres anvendelse for fremstilling av medikamenter for behandling av cancer NO327008B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01402460A EP1298125A1 (en) 2001-09-26 2001-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer
PCT/EP2002/011353 WO2003028721A2 (en) 2001-09-26 2002-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer

Publications (2)

Publication Number Publication Date
NO20041214L true NO20041214L (no) 2004-06-24
NO327008B1 NO327008B1 (no) 2009-04-06

Family

ID=8182891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041214A NO327008B1 (no) 2001-09-26 2004-03-23 Substituerte benzimidazolforbindelser og deres anvendelse for fremstilling av medikamenter for behandling av cancer

Country Status (35)

Country Link
US (1) US7041668B2 (no)
EP (2) EP1298125A1 (no)
JP (1) JP4510450B2 (no)
KR (1) KR100891439B1 (no)
CN (1) CN100346786C (no)
AR (1) AR037096A1 (no)
AT (1) ATE386517T1 (no)
AU (1) AU2002337151B2 (no)
BR (1) BR0212856A (no)
CA (1) CA2461622C (no)
CO (1) CO5570675A2 (no)
CY (1) CY1107953T1 (no)
DE (1) DE60225159T2 (no)
DK (1) DK1432417T3 (no)
EA (1) EA006802B1 (no)
ES (1) ES2301682T3 (no)
GT (1) GT200200190A (no)
HR (1) HRPK20040293B3 (no)
HU (1) HUP0401756A3 (no)
IL (1) IL161059A0 (no)
ME (1) MEP16808A (no)
MX (1) MXPA04002042A (no)
MY (1) MY135339A (no)
NO (1) NO327008B1 (no)
NZ (1) NZ531246A (no)
PA (1) PA8555501A1 (no)
PE (1) PE20030427A1 (no)
PL (1) PL369527A1 (no)
PT (1) PT1432417E (no)
PY (1) PY0223362A (no)
RS (1) RS50896B (no)
SI (1) SI1432417T1 (no)
UY (1) UY27452A1 (no)
WO (1) WO2003028721A2 (no)
ZA (1) ZA200401887B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
JP2007527412A (ja) * 2003-10-24 2007-09-27 エグゼリクシス， インコーポレイテッド Ｔａｏキナーゼモジュレーターおよび使用方法
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
UA92180C2 (en) * 2005-09-06 2010-10-11 Смиткляйн Бичам Корпорейшн Benzimidazole thiophene compounds as plk inhibitors
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
KR101608445B1 (ko) 2006-10-12 2016-04-01 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
PT2722046T (pt) * 2007-10-12 2017-03-15 Abbvie Ireland Unlimited Co Forma cristalina 1 de 2-((r)-2-metilpirrolidina-2-yl)-1hbenzimidazol- 4-carboxamida
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
FR2941952B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2011091152A1 (en) * 2010-01-22 2011-07-28 Pablo Gastaminza Inhibitors of hepatitis c virus infection
KR102096014B1 (ko) 2012-12-05 2020-04-03 알닐람 파마슈티칼스 인코포레이티드 PCSK9 iRNA 조성물 및 그 사용 방법
MX2018002158A (es) 2015-08-25 2018-07-06 Alnylam Pharmaceuticals Inc Mí‰TODOS Y COMPOSICIONES PARA TRATAR UN TRASTORNO ASOCIADO A GEN DE PROPROTEINA CONVERTASA SUBTILISINA KEXINA (PCSK9).

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2441201C2 (de) * 1974-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung
DE2541752A1 (de) * 1975-09-19 1977-03-24 Hoechst Ag Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
CY1107953T1 (el) 2013-09-04
ZA200401887B (en) 2005-05-31
ES2301682T3 (es) 2008-07-01
GT200200190A (es) 2003-11-11
SI1432417T1 (sl) 2008-08-31
BR0212856A (pt) 2004-09-14
EP1432417B1 (en) 2008-02-20
HRPK20040293B3 (hr) 2007-06-30
NO327008B1 (no) 2009-04-06
DE60225159D1 (de) 2008-04-03
JP2005504112A (ja) 2005-02-10
CN100346786C (zh) 2007-11-07
ATE386517T1 (de) 2008-03-15
IL161059A0 (en) 2004-08-31
DE60225159T2 (de) 2009-02-19
AU2002337151B2 (en) 2007-04-26
MXPA04002042A (es) 2004-06-07
WO2003028721A2 (en) 2003-04-10
PA8555501A1 (es) 2003-06-30
DK1432417T3 (da) 2008-06-16
NZ531246A (en) 2006-06-30
PE20030427A1 (es) 2003-06-20
PL369527A1 (en) 2005-05-02
HUP0401756A2 (hu) 2005-01-28
RS50896B (sr) 2010-08-31
PY0223362A (es) 2004-04-01
US20050014811A1 (en) 2005-01-20
CA2461622C (en) 2008-12-02
YU21404A (sh) 2006-08-17
EP1298125A1 (en) 2003-04-02
HUP0401756A3 (en) 2005-06-28
MY135339A (en) 2008-03-31
KR20040048904A (ko) 2004-06-10
EP1432417A2 (en) 2004-06-30
CA2461622A1 (en) 2003-04-10
EA006802B1 (ru) 2006-04-28
EA200400475A1 (ru) 2004-08-26
HRP20040293A2 (en) 2005-06-30
JP4510450B2 (ja) 2010-07-21
CO5570675A2 (es) 2005-10-31
KR100891439B1 (ko) 2009-04-03
US7041668B2 (en) 2006-05-09
CN1558761A (zh) 2004-12-29
UY27452A1 (es) 2003-02-28
MEP16808A (bs) 2010-06-10
PT1432417E (pt) 2008-05-23
HK1068551A1 (en) 2005-04-29
AR037096A1 (es) 2004-10-20
WO2003028721A3 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
NO20024610L (no) Synergistiske metoder og blandinger for behandling av kreft
EE200200673A (et) Kinasoliini derivaadid kasvajate raviks
NO20041216L (no) Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt
KR100695846B9 (ko) 암 치료
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
DK1432417T3 (da) Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer
NO20016149L (no) Indol-derivater og deres anvendelse for behandling av osteporose blant andre applikasjoner
IS6918A (is) Meðferð erfiðra æxla með notkun epóþílon afleiða
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
DK1176964T3 (da) Brug af ET743 til behandling af cancer
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
PL356784A1 (pl) Substancja do zastosowania w leczeniu łuszczycy
DE60223576D1 (de) Hautbehandlungszusammensetzung
NO20033498L (no) Fremgangsmåte for behandling og törking av trevirke
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
EE200200577A (et) Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees